CPI‐203 improves the efficacy of anti‐PD‐1 therapy by inhibiting the induced PD‐L1 overexpression in liver cancer

Hepatocellular carcinoma (HCC) is one of the commonest lethal malignancies worldwide, and often diagnosed at an advanced stage, without any curative therapy. Immune checkpoint blockers targeting the programmed death receptor 1 (PD‐1) have shown impressive antitumor activity in patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Xiaoge, Wang, Wei, Liang, Taizhen, Li, Shasha, Yang, Chan, Xu, Xinfeng, Li, Lin, Liu, Shuwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748230/
https://www.ncbi.nlm.nih.gov/pubmed/34727389
http://dx.doi.org/10.1111/cas.15190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748230/
https://www.ncbi.nlm.nih.gov/pubmed/34727389
http://dx.doi.org/10.1111/cas.15190

Ejemplares similares